Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment-Reference-Cited by-同舟云学术

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

Published:2014 Issue:1 Volume:2 Page:3
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:Journal for ImmunoTherapy of Cancer

Author:

Spranger Stefani,Koblish Holly K,Horton Brendan,Scherle Peggy A,Newton Robert,Gajewski Thomas F

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Reference44 articles.

1. Innate and adaptive immune cells in the tumor microenvironment

2. Gene Signature in Melanoma Associated With Clinical Activity

3. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

4. The immune contexture in human tumours: impact on clinical outcome

5. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

Cited by 482 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends;Experimental & Molecular Medicine;2024-09-02

2. Targeting amino acid-metabolizing enzymes for cancer immunotherapy;Frontiers in Immunology;2024-08-14

3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

4. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression;International Immunopharmacology;2024-08

5. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302);BMC Cancer;2024-07-25